Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 1
2014 2
2015 4
2016 9
2017 3
2018 7
2019 9
2020 5
2021 8
2022 11
2023 9
2024 12
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

74 results

Results by year

Filters applied: . Clear all
Page 1
Neutrophils Kill Antibody-Opsonized Cancer Cells by Trogoptosis.
Matlung HL, Babes L, Zhao XW, van Houdt M, Treffers LW, van Rees DJ, Franke K, Schornagel K, Verkuijlen P, Janssen H, Halonen P, Lieftink C, Beijersbergen RL, Leusen JHW, Boelens JJ, Kuhnle I, van der Werff Ten Bosch J, Seeger K, Rutella S, Pagliara D, Matozaki T, Suzuki E, Menke-van der Houven van Oordt CW, van Bruggen R, Roos D, van Lier RAW, Kuijpers TW, Kubes P, van den Berg TK. Matlung HL, et al. Among authors: menke van der houven van oordt cw. Cell Rep. 2018 Jun 26;23(13):3946-3959.e6. doi: 10.1016/j.celrep.2018.05.082. Cell Rep. 2018. PMID: 29949776 Free article.
Evaluating new treatments for anaplastic thyroid cancer.
Coca-Pelaz A, Rodrigo JP, Lopez F, Shah JP, Silver CE, Al Ghuzlan A, Menke-van der Houven van Oordt CW, Smallridge RC, Shaha AR, Angelos P, Mendenhall WM, Piazza C, Olsen KD, Corry J, Tufano RP, Sanabria A, Nuyts S, Nathan CA, Vander Poorten V, Dias FL, Suarez C, Saba NF, de Graaf P, Williams MD, Rinaldo A, Ferlito A. Coca-Pelaz A, et al. Among authors: menke van der houven van oordt cw. Expert Rev Anticancer Ther. 2022 Nov;22(11):1239-1247. doi: 10.1080/14737140.2022.2139680. Epub 2022 Nov 9. Expert Rev Anticancer Ther. 2022. PMID: 36283091 Review.
Molecular imaging predicts lack of T-DM1 response in advanced HER2-positive breast cancer (final results of ZEPHIR trial).
Mileva M, de Vries EGE, Guiot T, Wimana Z, Deleu AL, Schröder CP, Lefebvre Y, Paesmans M, Stroobants S, Huizing M, Aftimos P, Tol J, Van der Graaf WTA, Oyen WJG, Vugts DJ, Menke-van der Houven van Oordt CW, Brouwers AH, Piccart-Gebhart M, Flamen P, Gebhart G. Mileva M, et al. Among authors: menke van der houven van oordt cw. NPJ Breast Cancer. 2024 Jan 6;10(1):4. doi: 10.1038/s41523-023-00610-6. NPJ Breast Cancer. 2024. PMID: 38184611 Free PMC article.
Whole-Body HER2 Heterogeneity Identified on HER2 PET in HER2-Negative, -Low, and -Positive Metastatic Breast Cancer.
Eisses B, van Geel JJL, Brouwers AH, Bensch F, Elias SG, Kuip EJM, Jager A, van der Vegt B, Lub-de Hooge MN, Emmering J, Arens AIJ, Zwezerijnen GJC, Vugts DJ, Menke-van der Houven van Oordt CW, de Vries EGE, Schröder CP. Eisses B, et al. Among authors: menke van der houven van oordt cw. J Nucl Med. 2024 Oct 1;65(10):1540-1547. doi: 10.2967/jnumed.124.267636. J Nucl Med. 2024. PMID: 39237347
First exploration of the on-treatment changes in tumor and organ uptake of a radiolabeled anti PD-L1 antibody during chemoradiotherapy in patients with non-small cell lung cancer using whole body PET.
Pouw JEE, Hashemi SMS, Huisman MC, Wijngaarden JE, Slebe M, Oprea-Lager DE, Zwezerijnen GJC, Vugts D, Ulas EB, de Gruijl TD, Radonic T, Senan S, Menke-van der Houven van Oordt CW, Bahce I. Pouw JEE, et al. Among authors: menke van der houven van oordt cw. J Immunother Cancer. 2024 Feb 1;12(2):e007659. doi: 10.1136/jitc-2023-007659. J Immunother Cancer. 2024. PMID: 38302416 Free PMC article.
Circulating T cell status and molecular imaging may predict clinical benefit of neoadjuvant PD-1 blockade in oral cancer.
Wondergem NE, Miedema IHC, van de Ven R, Zwezerijnen GJC, de Graaf P, Karagozoglu KH, Hendrickx JJ, Eerenstein SEJ, Bun RJ, Mulder DC, Voortman J, Boellaard R, Windhorst AD, Hagers JP, Peferoen LAN, de Gruijl TD, Bloemena E, Brakenhoff RH, Leemans CR, Menke-van der Houven van Oordt CW. Wondergem NE, et al. Among authors: menke van der houven van oordt cw. J Immunother Cancer. 2024 Jul 22;12(7):e009278. doi: 10.1136/jitc-2024-009278. J Immunother Cancer. 2024. PMID: 39038919 Free PMC article.
Design, development and clinical translation of CriPec®-based core-crosslinked polymeric micelles.
Rijcken CJF, De Lorenzi F, Biancacci I, Hanssen RGJM, Thewissen M, Hu Q, Atrafi F, Liskamp RMJ, Mathijssen RHJ, Miedema IHC, Menke-van der Houven van Oordt CW, van Dongen GAMS, Vugts DJ, Timmers M, Hennink WE, Lammers T. Rijcken CJF, et al. Among authors: menke van der houven van oordt cw. Adv Drug Deliv Rev. 2022 Dec;191:114613. doi: 10.1016/j.addr.2022.114613. Epub 2022 Nov 4. Adv Drug Deliv Rev. 2022. PMID: 36343757 Review.
Current state and upcoming opportunities for immunoPET biomarkers in lung cancer.
Slebe M, Pouw JEE, Hashemi SMS, Menke-van der Houven van Oordt CW, Yaqub MM, Bahce I. Slebe M, et al. Among authors: menke van der houven van oordt cw. Lung Cancer. 2022 Jul;169:84-93. doi: 10.1016/j.lungcan.2022.05.017. Epub 2022 May 31. Lung Cancer. 2022. PMID: 35679715 Free article. Review.
74 results